Viral Antigens(病毒抗原)
A viral Antigen is an antigen with multiple antigenicities that is protein in nature, strain-specific, and closely associated with the virus particle. A viral antigen is a protein encoded by the viral genome.A viral protein is an antigen specified by the viral genome that can be detected by a specific immunological response.
Viruses are infectious pathogens that cause serious diseases & major threats for global public health, such as influenza, hepatitis, & AIDS. Virus is a sub-micrometer particle that has DNA or RNA packed in a shell called capsid. Viral antigens protrude from the capsid and often fulfill important function in docking to the host cell, fusion, and injection of viral DNA/RNA. Antibody-based immune responses form a first layer of protection of the host from viral infection; however, in many cases a vigorous cellular immune response mediated by T-cells and NK-cells is required for effective viral clearance. When cellular immunity is unable to clear the virus, the infection can become chronic, and serum antibodies to the viral pathogen are used as first indicator for the diagnosis of the disease.
ELISAs provide a valuable tool in the detection and diagnosis of virus infection. The ability to produce recombinant viral proteins will ensure that future ELISAs are safe, specific and rapid. Even when a virus cannot be cultured, provided gene sequence is available, it is possible to rapidly respond to emerging viruses and new viral strains of existing pathogens.
Recombinant viral antigens contain part of viral sequence meaning that the recombinant antigen contains a region which can be recognized by different antibodies produced by different individuals. This reduces the risk of false negatives which can occur with synthetic peptides, which contain only a small portion of the entire protein. If an individual infected with a viral antigen makes antibodies to a part of the protein not included in the synthetic peptides, a false negative results.
Recombinant viral protein usually contains a fusion protein/partner which produces superior attachment to assay surfaces such as wells. For this reason, smaller amounts of recombinant protein will produce the same results as larger amounts of unfused protein. The choice of fusion partner prevents false positives, allowing superior adhesion without incorrect results.
Recombinant Viral proteins are expressed in bacteria, yeast, mammalian cells, and viruses. E. Coli cells were first to be used for this purpose but the expressed proteins were not glycosylated, which was a major drawback since many of the immunogenic proteins of viruses such as the envelope glycoproteins, were glycosylated. Nevertheless, in many instances, it was demonstrated that the non-glycosylated protein backbone was just as immunogenic. The obvious advantage of recombinant viral antigens is that they are available in unlimited quantities and the production and quality control processes is simple.
Advantages of defined using recombinant viral antigens:
1. Production and quality control is simple.
2. No nucleic acids or other viral or external proteins, therefore less toxic.
3. Safer in cases where viruses are oncogenic or establish a persistent infection.
4. Feasible even if virus cannot be cultivated
Disadvantages:
1. May be less immunogenic than conventional inactivated whole-virus vaccines.
2. Requires adjuvant .
3. Fails to elicit CMI.
Facts about Viral Antigens:
1. A Viral Protein Mimics its Way into cells.
2. Viral Protein Helps Infected T Cells Stick To Uninfected Cells.
3. The Viral Protein A238L Inhibits Cyclooxygenase-2 Expression through a Nuclear Factor of Activated T Cell-dependent Trans-activation Pathway.
4. Viral Protein is an effective preventative against ear infection.
5. HIV-1 Viral Protein R Induces Apoptosis via a Direct Effect on the Mitochondrial Permeability Transition Pore.
6. The Level of Viral Antigen Presented by Hepatocytes Influences CD8 T-Cell Function.
7. Antigen-presenting cells from calves persistently infected with bovine viral diarrhea virus, a member of the Flaviviridae, are not compromised in their ability to present viral antigen.
8. There is a difference in the distribution and spread of a viral antigen, development of lesions and correlation between presence of viral antigen and lesions.
9. The absence of viral antigens on the surface of equine herpesvirus-1-infected peripheral blood mononuclear cells is a strategy to avoid complement-mediated lysis.
10. Viral Protein Influences Key Cell-signaling Pathway.
11. A viral protein produced by cancer-causing virus influences a key signaling pathway in the immune cells that the virus infects. This stimulates the cells to divide, helping the virus spread through the body.
12. Protection by recombinant viral proteins against a respiratory virulent avian metapneumovirus has been achieved.
13. Viral O-acetylesterases are found in influenza C viruses and Corona-viruses. Viral O-acetylesterases remove cellular receptors from the surface of target cells which destroys the receptor. Recombinant viral O-acetylesterases derived from Sf9 insect cells as chimeric proteins fused to eGFP specifically hydrolyze 9-O-acetylated sialic acids, while that of sialodacryoadenitis virus, a rat coronavirus related to mouse hepatitis virus, is specific for 4-O-acetylated sialic acid. The recombinant esterases were shown to specifically de-O-acetylate sialic acids on glycoconjugates. The recombinant viral proteins can be used to unambiguously identify O-acetylated acids.
Products for Viral Antigens
- Borrelia(28)
- Chagas(3)
- Chikungunya(7)
- Chlamydia(10)
- Cytomegalo(8)
- Dengue(49)
- Ebola(4)
- EBV(10)
- Encephalitis(8)
- Feline Leukemia Virus(1)
- Hantavirus(1)
- HBsAg(8)
- Helicobacter Pylori(3)
- Hepatitis A(15)
- Hepatitis B(10)
- Hepatitis C(85)
- Hepatitis D(1)
- Hepatitis E(5)
- Herpes(11)
- HERV-K(1)
- HIV(141)
- HTLV(6)
- Influenza(69)
- Lassa(2)
- Malaria(72)
- Mumps(1)
- Mycoplasma(4)
- Norovirus(4)
- Papillomavirus(5)
- Parvovirus(3)
- Rubella(3)
- S. Typhi(5)
- SARS(84)
- Shiga Like Toxin(2)
- Toxoplasma(9)
- Treponema(16)
- Varicella(3)
- West Nile(2)
- Zika(13)
- Cat.No. 产品名称 Information
- GP25493 H3N2 Wisconsin H3N2 Influenza Virus-A Wisconsin/67/05 Recombinant
- GP25492 H3N2 Wyoming H3N2 Influenza-A Virus Wyoming/3/2003 Recombinant
- GP25491 Vietnam HN31242/2007 Hemagglutinin-Influenza A Virus H5N1 Vietnam HN31242/2007 Recombinant
- GP25490 H7N7 Netherlands H7N7 Influenza-A Virus Netherlands/219/03 Recombinant
- GP25489 H1N1 California H1N1 Influenza Virus California/04/2009 Recombinant
- GP25488 Influenza-A H1N1 New Caledonia H1N1 Influenza-A Virus New Caledonia/20/99 Recombinant
- GP25487 Parvovirus B19 VLP VP1 Parvovirus VLP VP1 Recombinant
- GP25486 Parvovirus B19 VLP VP1/VP2 Parvovirus B19 VLP VP1/VP2 Co-Capsid Recombinant
- GP25485 Parvovirus B19 VLP VP2 Parvovirus B19 VLP VP2 Recombinant
- GP25484 Zika Envelope Domain-3 Zika Envelope Domain-III Recombinant
- GP25483 Zika Ectodomain Zika Ectodomain Recombinant
- GP25482 Zika Envelope, sf9 Zika Envelope Recombinant, sf9
- GP25481 Zika NS1, sf9 Zika NS1 Protein Recombinant, sf9
- GP25480 Zika NS1, HEK Zika NS1 Protein Recombinant, HEK
- GP25479 Zika NS1 Zika NS1 Protein Recombinant
- GP25478 Zika Envelope N Zika Envelope N-Terminal Recombinant
- GP25477 Zika Envelope F.Length Zika Envelope Full Length Protein Recombinant
- GP25476 Zika Envelope Zika Envelope Recombinant
- GP25475 CHIKV E2 Chikungunya E2 Recombinant
- GP25474 CHIKV E1 Chikungunya E1 Recombinant
- GP25473 CHIKV Mutant Chikungunya Mutant (A226V) E1 Recombinant
- GP25472 Chikungunya E1 Chikungunya Wild Type E1 Recombinant
- GP25471 Norovirus Group-2 P-Domain Norovirus Group-2 Capsid P-Domain Recombinant
- GP25470 Norovirus Group-1 P-Domain 诺如病毒 Group-1 衣壳 P 域重组体
- GP25469 Norovirus Group-2 Norovirus Group-2 Capsid Recombinant
- GP25468 Norovirus Group-1 Norovirus Group-1 Capsid Recombinant
- GP25467 Ebola Sudan Protein Ebola Sudan Recombinant Protein
- GP25466 Ebola Zaire VP40 Ebola Zaire VP40 Recombinant
- GP25465 Ebola Zaire GP Ebola Zaire Glycoprotein Recombinant
- GP25464 Ebola Zaire Protein Ebola Zaire Recombinant Protein
- GP25463 Rubella Capsid Rubella Virus Capsid C Recombinant
- GP25462 Rubella E2 Rubella Virus E2 Recombinant
- GP25461 Rubella E1 Rubella Virus E1 Mosaic Recombinant
- GP25460 Lassa GP1 Lassa Glycoprotein-1 Recombinant
- GP25459 Lassa Capsid Lassa Capsid Recombinant
- GP25458 TBEV preM Tick-Borne Encephalitis Virus preM Recombinant
- GP25457 TBEV NS3 Tick-Borne Encephalitis Virus NS3 Recombinant
- GP25456 TBEV Core Tick-Borne Encephalitis Virus Core Protein Recombinant
- GP25455 JEV 日本脑炎病毒ENV重组体
- GP25454 TBEV gE C-end Tick-Borne Encephalitis Virus gE C-end Recombinant
- GP25453 TBEV gE middle Tick-Borne Encephalitis Virus gE Middle Recombinant
- GP25452 TBEV NE Tick-Borne Encephalitis Virus NE Recombinant
- GP25451 TBEV gE Tick-Borne Encephalitis Virus gE Recombinant
- GP25450 EBNA1BP2 Human EBNA1 Binding Protein 2 Human Recombinant
- GP25449 EBV p23, His Epstein-Barr Virus (HHV-4) p23 Recombinant, His Tag
- GP25448 EBV p23 Epstein-Barr Virus (HHV-4) p23 Recombinant
- GP25447 EBV p18 M Epstein -Barr 病毒 (HHV-4) p18 镶嵌重组体
- GP25446 EBV p18, GST Epstein - Barr virus (HHV-4) p18 Recombinant, GST Tag
- GP25445 EBV p18 Epstein-Barr Virus (HHV-4) p18 Recombinant
- GP25444 EBV EA Epstein-Barr virus (HHV-4) Early Antigen Recombinant